

CUMULATIVE INDEX 1997

Volume 13

January	UPDATE ON NEUROLOGIC CRITICAL CARE, pages 1-233
April	INTERNATIONAL PERSPECTIVES ON CRITICAL CARE, pages 235-457
July	COMMON ISSUES IN PEDIATRIC AND ADULT CRITICAL CARE, pages 459-707
October	MEDICAL TOXICOLOGY, pages 709-959

Note: Page numbers of article titles are in **boldface** type

- Abrin, poisoning by, 850-854
- ACE inhibitors, for hypertension in
intracerebral hemorrhage, 152-153
- N-Acetylcysteine, for anticonvulsant
hypersensitivity syndrome, 736-737
- Aconitine, poisoning by, 867-870
structure of, 868
- Acquired immunodeficiency syndrome
(AIDS), ARF in, **523-552**. See also
*Acute respiratory failure (ARF), in AIDS
patients*.
- Action potentials, cardiac, voltage-gated
sodium channels and, 830-833
phases of, 831-833
- Activated charcoal, multiple-dose, in
gastrointestinal decontamination
following poisoning, 722-723
versus gastric emptying, in gastrointesti-
nal decontamination following poi-
soning, 715-717
- Acute renal failure, **575-590**
causes, 576-581
drug-related, 580-581
glomerular, 579-580
hypoxic-ischemic, 576-579
renal hypoperfusion, 576-579
vascular, 579-580
clinical features, 581-583
defined, 575-576
dialysis modalities for, 584-585
in adults, causes, 578-579
in children, causes, 578
in newborns and infants, causes, 577-
578
management, conservative, 583-584
- Acute respiratory distress syndrome
(ARDS), **503-521**
clinical features, 506-508
defined, 504-508
management, 508-511
airway pressure release ventilation,
515
ECCO₂-R, 514-515
ECMO, 514-515
high-frequency ventilation, 513-514
inverse ratio ventilation, 512-513
IPPV, 510-511
IVOX, 515
liquid ventilation, 516-517
nitric oxide, 515-516
PEEP, 511-513
permissive hypercapnia, 512
pharmacologic agents, 517-518
surfactants, 515
pathophysiology, 505-506
sepsis and, 507-508
- Acute respiratory failure (ARF), in AIDS
patients, **523-552**
causes, 523-526
diagnostic approach to, 527-531
pathophysiology, 527
pneumothoraces complicating,
537-538
prognostic factors, 538-543
respiratory isolation issues related to,
526-527
survival rates, 538-543
treatment, 531-538

Acute respiratory failure (ARF) (*Continued*)

- CAPA, 534-536
- clindamycin, 534
- corticosteroids, 532-533
- eflornithine, 534
- mechanical ventilation, 536-537
- pentamine isethionate, 532
- primaquine, 534
- TMP-SMZ, 531-532
- trimetrexate, 533-534
- in children with AIDS, 543-545
- in HIV-seropositive patients, 523-552.
 - See also *Acute respiratory failure (ARF)*, in *AIDS patients*.
- Adrenal insufficiency, following septic shock, in adults, 567
- in children, 558
- β -Adrenergic blockers, for hypertension in intracerebral hemorrhage, 151
- α -Adrenergic blockers, for hypertension in intracerebral hemorrhage, 151
- Advocacy, in ICU, 698-699
- Africa, aid for, 259
- Baragwanath Hospital in, admissions decisions of consultant in, 261-262
- critical care in, 255-265
 - equipment for, 259
 - organization of, 257-258
 - patient mix in, 260
 - staffing for, 259
 - training for, 256-257
 - for doctors, 257
 - for nurses, 257-258
 - for technologists, 257
- life in, described, 255
- limited resources in, 260-262
- cost containment in presence of, 262-263
- population of, 255
- size of, 255
- β_2 -Agonists, for status asthmaticus, 464-465
- Airway pressure release ventilation, for ARDS, 515
- Alkaloid(s), *Veratrum*, poisoning by, 864-867
- Amebiasis, in South American ICUs, 380
- Aminobutyric acid (GABA), enhanced activity of, drugs in, 741-742
- Analgesia, in crotalid snake envenomation treatment, 908
- Anesthesia/anesthetics, critical care and, 442-443
 - for status asthmaticus, 471-472
- Anthropometry, in nutritional status assessment, 670
- Antibiotic(s), convulsions due to, 741-762.
 - See also *Convulsion(s)*, *antibiotic-induced*.
- Anticholinergic agents, for status asthmaticus, 466

- poisoning by, 875-879
- Anticholinergic poisoning syndrome, 802-804
- Anticoagulant(s), overdose of, 603-606
- Anticonvulsant(s), aromatic, formation of arene oxides by, 732
- Anticonvulsant hypersensitivity syndrome, 727-739
 - adverse effects associated with, 731
 - described, 727
 - diagnosis, 736
 - felbamate in, 734-736
 - incidence, 727
 - pathophysiology, 730-736
 - phenobarbital in, 730
 - phenytoin in, 729-730
 - signs and symptoms, 728-730
 - treatment, 736-737
- Antihypertensive agents, for hypertension in intracerebral hemorrhage, 148-153
- Antivenin, in crotalid snake envenomation treatment, 909-914
- ARDS. See *Acute respiratory distress syndrome (ARDS)*.
- ARF. See *Acute respiratory failure (ARF)*.
- Arginine, in nutritional status assessment, 677
- Arrhythmia(s), ventricular, sodium channel blocking agent-related, 834
- treatment, 843-844
- Arteriovenous fistulas, cerebral, detection of, 73
- Arthralgia(s), in anticonvulsant hypersensitivity syndrome, 729
- Ascariasis, in South American ICUs, 380
- Asia, East, critical care in, 287-298
 - cost of, 295-296
 - research related to, 296
 - types of, 289-290
- developing countries of, health trends in, 288-289
- economic growth in, 287
- ICUs in, 290-295
- per capita annual income in, 287
- population of, 287
- Asthma. See also *Status asthmaticus*.
 - care of patient with, 459-460
 - characteristics of, 459
 - clinical assessment, 462-463
 - epidemiology, 460
 - pathophysiology, 460-461
- Atropine, in nerve agent poisoning treatment, 936-937
- Australia, critical care in, 299-316
 - consultants for, 303-304
 - incident monitoring study in, 311-312
 - international links in, 313-314
 - manpower for, 307-309
 - MOPS in, 312-313
 - nurses in, 304-305

- organization of, 302-305
 - pediatric, 305
 - quality assurance in, 310-312
 - staffing of, 302-305
 - training for, 306-307
 - FICANZCA program, 307
 - RACP program, 306-307
- geography of, 299-300
- health system organization in, 300-301
- history of, 301-302
- population of, 299
- Australian and New Zealand Intensive Care Society (ANZICS), 309-310
- Autonomic dysfunction, in Guillain-Barré syndrome, 8-9
- Autonomic failure, in Guillain-Barré syndrome, 8-9
- Autoregulation, cerebrovascular reactivity and, 140
 - described, 133
 - metabolic, 164
 - pressure, 165
- A-VDO₂, monitoring of, in traumatic brain injury, 172-174
- Baragwanath Hospital, in Africa,
 - admission decisions of consultant in, 261-262
- Benzodiazepine(s), for anticonvulsant hypersensitivity syndrome, 737
- Benzylopicillin, seizures due to, 745-749
- Biochemical markers, in nutritional status assessment, 670-671
- Bite(s), snake, in South American ICUs, 382
- Blood pressure control, in intracerebral hemorrhage, 147-148
- Blood products, in crotalid snake envenomation treatment, 909-914
- Blood-brain barrier, low hydraulic conductivity of, 109-110
 - Starling forces and, 109
- Bradyarrhythmia(s), sodium channel blocking agent-related, 835-836
 - treatment, 844-845
- Brain, pathophysiology of, 164-171
 - physiology of, 164-171
- Brain attack, 201
- Brain death, determination of, transcranial Doppler ultrasonography in, 98-99
- Brain injury, catabolism following,
 - management, nutritional support in, 40
 - high-protein enteral feedings following, 41-45
 - hypermetabolism following, management, nutritional support in, 40
 - metabolic sequelae of, management, nutritional support in, 39-49
 - traumatic. See *Traumatic brain injury.*
- Brain protection, etomidate and, 190-192
 - history of, 186-187
 - inhalational agents and, 189-190
 - intravenous agents and, 185-199
 - ketamine and, 194-195
 - metabolic theory, 187-189
 - propofol and, 192-194
 - receptor theory, 189
- Brain storming, in critical care medicine, 433
- Brain swelling, following head injury, 617-619
- Bronchoscopy, for status asthmaticus, 468
- Burn(s), nutrition and, 681
- Burnout, in ICU, 697-698
- BZD receptor binding, in antibiotic-induced convulsions, 744-745
- Calcium channel blockers, for
 - hypertension in intracerebral hemorrhage, 151-152
- Calorie requirements, of critically ill neurologic patients, 40-41
- Calorimetry, indirect, in nutritional status assessment, 671-672
- Canada, critical care in, 347-362
 - costs of, 355-356
 - education for, 356-358
 - future challenges for, 359-361
 - historic milestones in, 348-350
 - research related to, 358-359
 - services related to, 352-355
 - U.S. critical care and, comparison between, 350-359
- Carbamazepine, hypersensitivity associated with, 730
 - structure of, 735
- Carbapenem(s), seizures due to, 751-752
- Carbohydrates, in nutritional status assessment, 674-675
 - versus fat, in critically ill neurologic patients, 44-45
- Carbon dioxide reactivity, 169-171
- Cardiac action potentials, voltage-gated sodium channels and, 830-833
- Cardiac glycosides, poisoning by, 859-862
- Cardiovascular system, nerve agents
 - effects on, 930-931
 - nutritional effects on, 679-680
 - septic shock in children effects on, 558-560
- Cardiovascular therapy, following septic shock in adults, 566-567
- Cardiovascular toxicity, 897
- Catabolism, following neurologic injuries, 40
- Catheter(s), jugular bulb. See *Jugular bulb catheter.*

- Cefazolin, seizures due to, 749-750
- Central anticholinergic syndrome, 876
- Central nervous system (CNS), nerve agents effects on, 930
- Cephalosporin(s), seizures due to, 749-751
- Cephalothin, seizures due to, 749
- Cerebral blood flow, and oxygen metabolism, relationship between, 165-167
- following traumatic brain injury, 171-172
- head injury effects on, 614-617
- Cerebral hyperemia, mannitol and, 120-121
- Cerebral ischemia, acute, transcranial Doppler ultrasonography in, uses and considerations, 99-100
- described, 133-134
- pathophysiology, 186
- Cerebral metabolism, following traumatic brain injury, 172
- Cerebral oxygen delivery, and consumption, 51-60
- described, 51-52
- Cerebral vasospasm, detection of, transcranial Doppler ultrasonography in, 88-91
- following subarachnoid hemorrhage, development of, 87-88
- in head-injured patients, diagnosis, 72-73
- monitoring of, transcranial Doppler ultrasonography in, 91-92
- Cerebral venous circulation, anatomy of, 61-62
- Cerebroocclusive vascular disease. See *Stroke*.
- Cerebrovascular reactivity, and autoregulation, 140
- Cerebrovascular system, physiology of, 133-139
- Chagas' disease, in South American ICUs, 383
- Charcoal, activated, multiple-dose, in gastrointestinal decontamination following poisoning, 722-723
- versus gastric emptying, in gastrointestinal decontamination following poisoning, 715-717
- Chemical debulking, in osmotherapy, 118
- Chemical warfare, 923-942. See also *Nerve agents, poisoning by*.
- Chest pain, cocaine use and, 809-828
- differential diagnosis, 815-816
- disposition of patients with, 822-824
- evaluation, 816-818
- pathogenesis, 813-815
- treatment, 818-822
- Children, acute renal failure in, causes, 578
- ICUs for, in Australia, 305
- in India, 331-346. See also *India, critical care in, neonatal and pediatric*.
- sepsis in, 553-563
- submersion injuries in. See *Submersion injuries, in children*.
- with AIDS, ARF in, 543-545
- Cicutoxin, poisoning by, 854-858
- structure of, 857
- Cilastatin, seizures due to, 751-752
- Circulation, cerebral venous, anatomy of, 61-62
- Cisternal irrigation, prolonged, for subarachnoid hemorrhage, 214-215
- Cl⁻ ionophore binding, in antibiotic-induced convulsions, 744
- Clindamycin, for ARF in AIDS patients, 534
- Clonazepam, for status epilepticus, 27
- CNS. See *Central nervous system (CNS)*.
- Coagulopathy(ies), acquired, 591-609
- consumptive, 592-602
- DIC, 592-597
- crotalid snake envenomation and, 895-896
- iatrogenic, 602-606
- Cocaine use, chest pain following, 809-828.
- See also *Chest pain, cocaine use and*.
- pharmacology associated with, 810-813
- Codeine, for pain in Guillain-Barré syndrome, 10
- Communications, international organizations and, 441-452
- Internet connections in, 445-451
- links in, 445
- original organizations, 443
- regional organizations, 445
- Consensus, defined, 417
- in critical care medicine, 417-439
- Consensus conferences, in critical care medicine, 417-439
- purposes of, 419
- Consent, informed, ethical issues related to, 413
- Continuous positive airway pressure (CPAP), for ARF in AIDS patients, 534-536
- Convulsion(s), antibiotic-induced, 741-762
- agents in, 745-757
- carbapenems in, 751-752
- cephalosporins in, 749-751
- fluoroquinolones in, 752-754
- isoniazid in, 754-757
- mechanisms of, 744-745
- BZD receptor binding, 744-745
- Cl⁻ ionophore binding, 744
- direct GABA antagonism, 744
- indirect GABA antagonism, 744-745
- inhibition of GABA synthesis, 745
- metronidazole in, 757
- penicillins in, 745-749

- risk factors for, 758
 GABA_A receptor complex in, 742-744
 Corticosteroid(s), for anticonvulsant hypersensitivity syndrome, 737
 Corticosteroid(s), for ARF in AIDS patients, 532-533
 for status asthmaticus, 465
 in crotalid snake envenomation treatment, 908
 Cost containment, in Africa, in presence of limited resources, 262-263
 CPAP. See *Continuous positive airway pressure (CPAP)*.
 Critical care. See also *Intensive care; Intensive care units (ICUs)*.
 and anesthesia, 442-443
 consensus conferences in, 417-439
 alternative methods, 433-436
 archetypes of, 420-422
 ad-hoc process, 421-422
 French national process, 421
 NIH process, 420-421
 brain storming, 433
 decision mapping, 434-435
 Delphi method, 434
 integrative group process, 434-435
 literature evaluation, 430-431
 methods of, 422-430
 foundations of, 436-438
 nominal group technique, 433
 panel meeting activities, 428-430
 panel recommendations, 430
 panelist selection, 431
 performance evaluation, 432-433
 preconference activities, 422-428
 RAND appropriateness rating method, 435-436
 rationale for recommendations, 431
 state-of-the-art process, 436
 structuring of recommendations, 431-432
 defined, 236
 ethics in, international perspectives on, 409-415
 international perspectives on. See also *Ethical issues, in critical care, international perspectives on*.
 history of, 235-236
 in Africa, 255-265. See also *Africa, critical care in*.
 in Australia, 269-316. See also *Australia, critical care in*.
 in Canada, 347-362. See also *Canada, critical care in*.
 in East Asia, 287-298. See also *Asia, East, critical care in*.
 in Europe, 245-254. See also *Europe, critical care in*.
 in India, 317-329. See also *India, critical care in*.
 in Japan, 267-277. See also *Japan, intensive care wards in*.
 in Korea, 277-285. See also *Korea, intensive care wards in*.
 in New Zealand, 299-316. See also *New Zealand, critical care in*.
 in South America, 377-387. See also *South America, critical care in*.
 in United States, 363-376. See also *United States, critical care in*.
 neonatal, in India, evolution of, 331-346.
 See also *India, critical care in, neonatal and pediatric*.
 outcome and resource consumption in, international comparison between, 389-407. See also *Health care, international comparisons of*.
 pediatric, in India, evolution of, 331-346.
 See also *India, critical care in, neonatal and pediatric*.
 worldwide, establishment of, 442-445
 Cromomes, for status asthmaticus, 467
 Crotalid snake envenomation, 889-921
 cardiovascular toxicity associated with, 897
 clinical presentation, 898-902
 coagulopathy associated with, 895-896
 determination of, 905-906
 epidemiology, 890-891
 hematologic disorders associated with, 900-901
 neuromuscular toxicity associated with, 901
 neurotoxicity associated with, 897
 pathophysiology, 891-897
 thrombocytopenia associated with, 896-897
 tissue damage associated with, 892-895, 898-900
 treatment, 902-915
 analgesia in, 908
 blood products in, 909-914
 corticosteroids in, 908
 cryotherapy in, 903
 electric shock therapy in, 905
 excisional therapy in, 915
 fasciotomy in, 914-915
 fluid replacement in, 906
 heat application in, 903
 immobilization in, 902
 incision and suction in, 904
 inhospital, 905-914
 prehospital, 902-905
 pressure immobilization in, 903
 snake venom extractors in, 904
 surgical, 914-915
 tourniquets in, 903-904
 wound care in, 906-908
 Cryotherapy, in crotalid snake envenomation treatment, 903

- Decision mapping (DM), in critical care medicine, 434-435
- Decontamination, gastrointestinal, following poisoning, **709-725**. See also *Gastrointestinal decontamination, following poisoning*, in nerve agent poisoning treatment, 934-935
- Dehydration, osmotherapy and, 121-122
- Delphi method, in critical care medicine, 434
- Dengue hemorrhagic fever, in South American ICUs, 382
- Dialysis, for acute renal failure, 584-585
- Diazepam, for status epilepticus, 26
- Diazoxide, for hypertension in intracerebral hemorrhage, 150
- DIC. See *Disseminated intravascular coagulation (DIC)*.
- Digitoxin, structure of, 860
- Dilantin sensitivity, 729-730
- Disaster medicine, intensive care unit and, 241
- Disseminated intravascular coagulation (DIC), 592-597
causes, 593
clinical presentation, 594-595
following septic shock in children, 561-562
management, 595-597
pathophysiology, 593-594
- Diving reflex, 487-488
- DL- α -fluoromethyl-ornithine, for ARF in AIDS patients, 534
- Drowning, defined, 477
in males versus females, 478-479
near, defined, 477
prevalence, 478
secondary, defined, 477-478
wet versus dry, 485-486
- Drowning safety enactment, 484-485
- Drug(s), acute renal failure due to, 580-581
hyperthermia due to, **785-808**. See also *Hyperthermia, drug-induced*, serotonergic potential of, 771
- Drug overdose, **647-667**
- Dural sinus venous thrombosis, 219-221
- East Asia, critical care in, **287-298**. See also *Asia, East, critical care in*.
- Eastern Europe, critical care in, 250-251
- ECCO₂-R, for ARDS, 514-515
- ECMO. See *Extracorporeal membrane oxygenation (ECMO)*.
- Edema, and hypertension, 144-145
intracerebral hemorrhage and, 143-145
- Education, for ICUs in Korea, 281-282
in submersion injury prevention in children, 481-482
- Eflornithine, for ARF in AIDS patients, 534
- Electric shock therapy, in crotalid snake envenomation treatment, 905
- Electroencephalography (EEG), in status epilepticus, 22-24
- Electrolyte balance, following septic shock in children, 562
- Electrolyte disturbances, osmotherapy and, 121-122
- Emergency medical services, in Japan, 273
- Emergency medicine, intensive care unit and, 240
- Emesis, induced, versus gastric lavage, in gastrointestinal decontamination following poisoning, 709-715
- Encephalopathy, hypertensive, 136-137
- Enteral nutrition, of critically ill neurologic patients, 41-45
versus parenteral nutrition, of critically ill neurologic patients, 47-48
- Enteritis, in South American ICUs, 381
- Epidemiology, and preventative medicine, 239-240
- Ethic(s), in ICU, **691-701**
- Ethical issues, in ICUs, described, 409
in India, 324-325
in Western Europe, 249-250
informed consent, 413
international perspectives on, **409-415**
principles of, 410
triage and, 410-411
withholding and withdrawing treatments, 412-413
in neonatal ICU in India, 344
of intensivists, 240
- Etomidate, and neuroprotection, 190-192
for status epilepticus, 30
- Europe, critical care in, **245-254**
current status of, 246-251
future aims of, 251, 253
historical background, 245-246
societies of, 251, 252
Eastern, critical care in, 250-251
Western, critical care in, 246-250
bed occupancy of, 247
ethical issues related to, 249-250
ICUs in, number of, 246
nosocomial infection in, 250
patient demography in, 248-249
severity of illness scores and protocols in, 249
staffing of, 247-248
unit size of, 247
unit structure of, 247
- Excisional therapy, in crotalid snake envenomation treatment, 915
- Extracorporeal membrane oxygenation (ECMO), for ARDS, 514-515
for status asthmaticus, 468
- Extracorporeal therapies, following septic shock in children, 562

- Eye(s), nerve agents effects on, 931
- Fasciotomy, in crotalid snake envenomation treatment, 914-915
- Fat, versus carbohydrates, in critically ill neurologic patients, 44-45
- FCE22101, seizures due to, 751-752
- Federación Panamericana y Iberica de Medicina Crítica y Terapia Intensiva (FEPIMCTI), 377-379
- Felbamate, anticoagulant hypersensitivity syndrome due to, 734-736
for anticonvulsant hypersensitivity syndrome, 737
structure of, 735
- Fever, in anticonvulsant hypersensitivity syndrome, 728
- Fibrin(ogen)olysis, primary, 598-600
- FICANZCA program, 307
- Fistula(s), arteriovenous, cerebral, detection of, 73
- Fluid replacement, in crotalid snake envenomation treatment, 906
- Fluoroquinolone(s), seizures due to, 752-754
- Fosphenytoin, for status epilepticus, 27-28
- Furosemide, for status asthmaticus, 467
- GABA. See *Aminobutyric acid (GABA)*.
- GABA_A receptor complex, 742-744
- Gabapentin, for anticonvulsant hypersensitivity syndrome, 737
for pain in Guillain-Barré syndrome, 11
- Ganglionic blockers, for hypertension in intracerebral hemorrhage, 150-151
- Gastric emptying, in gastrointestinal decontamination following poisoning, effect on clinical outcome, 717-722
versus activated charcoal, in gastrointestinal decontamination following poisoning, 715-717
- Gastric lavage, versus induced emesis, in gastrointestinal decontamination following poisoning, 709-715
- Gastrointestinal decontamination, comparison studies of, 711-713
following poisoning, 709-725
gastric emptying in, effect on clinical outcome, 717-722
versus activated charcoal, 715-717
induced emesis versus gastric lavage in, 709-715
multiple-dose activated charcoal in, 722-723
whole bowel irrigation in, 722
outcome studies of, 718-719
- Gastrointestinal system, nerve agents effects on, 932
- Genitourinary system, nerve agents effects on, 932
- Glutamine, in nutritional status assessment, 675
- Glycoside(s), cardiac, poisoning by, 859-862
saponin, poisoning by, 879-883
- Grayanotoxin(s), poisoning by, 862-864
- Grayanotoxin I, structure of, 864
- Guillain-Barré syndrome, 1-15
acute neuromuscular weakness due to, 1
autonomic dysfunction in, 8-9
autonomic failure in, 8-9
clinical presentation, 2-3
described, 1
diagnosis, 3-4
geographic distribution of, 1
immunoglobulin for, 12
incidence, 1
management, ICU, 4, 5, 11
mechanical ventilation in, criteria for, 6
mortality rates, 1-2
nutrition in, 9-10
pain control in, 10-11
plasma exchange for, 11-12
respiratory failure in, 4-8
suxamethonium in, 9
- Harris-Benedict equation, 673
- Head injuries, 611-628
brain swelling following, 617-619
cerebral blood flow affected by, 614-617
intensive care following, 622-623
motor vehicle-related accidents and, 611
neurologic assessment, 612-613
outcome following, 623-624
resuscitation following, 620-622
secondary injury resulting from, 613-614
seizures following, 619-620
types, 612
- Head trauma, cerebral vasospasm due to, diagnosis, 72-73
jugular venous oxygen saturation following, optimal values for, 69-70
transcranial Doppler ultrasonography in, 93-94
uses, 97-98
transcranial Doppler ultrasonography waveforms in, 94-97
- Health and Welfare Ministry, of Japan, approval of intensive care wards by, 269
- Health care, international comparisons of, 387-407
at-risk population in, 390-392
cross-sectional versus longitudinal study design in, 396

Health care (*Continued*)

- ICU population in, 392-394
 - intrasystem heterogeneity in, 403
 - morbidity rates, 399-401
 - mortality rates, 397-399
 - outcome of, 396-403
 - resource consumption, 401-403
 - risk adjustment models in, 394-395
 - Heat, in crotalid snake envenomation treatment, 903
 - Heliox, for status asthmaticus, 467
 - Hematologic abnormalities, in anticonvulsant hypersensitivity syndrome, 729
 - Hematologic disorders, crotalid snake envenomation and, 900-901
 - Hemolytic-uremic syndrome (HUS), 597-598
 - Hemorrhage, intracerebral, thrombolytic therapy for. *See Intracerebral hemorrhage.*
 - intracranial, transcranial Doppler ultrasonography in, uses, 100
 - intraventricular, thrombolytic therapy for, 217-219
 - subarachnoid. *See Subarachnoid hemorrhage.*
 - Heparin, anticoagulant effects of, 605-606
 - High-frequency ventilation, for ARDS, 513-514
 - Hookworm disease, in South American ICUs, 380
 - Hydralazine, for hypertension in intracerebral hemorrhage, 150
 - Hyoscyamine, structure of, 876
 - Hypercapnia, permissive, for ARDS, 512
 - for status asthmaticus, 470-471
 - Hyperemia, cerebral, mannitol and, 120-121
 - Hypermetabolism, following neurologic injuries, 40
 - Hyperosmolar state, and osmotic compensation, osmotherapy and, 122-123
 - Hypersensitivity, to carbamazepine, 730
 - to phenobarbital, 730
 - to phenytoin, 729-730
 - Hypertension, and intracerebral hemorrhage extension, 142-143
 - and intracerebral hemorrhage outcome, relationship between, 146-147
 - described, 134-135
 - edema and, 144-145
 - in acute intracerebral hemorrhage, 131-161. *See also Intracerebral hemorrhage, hypertension in.*
 - intracranial, treatment, 71-73
 - Hypertensive encephalopathy, 136-137
 - Hyperthermia, consequences of, 787
 - drug-induced, 785-808
 - anticholinergic poisoning syndrome, 802-804
 - general mechanisms of, 786-787
 - malignant hyperthermia, 789-793
 - neuroleptic malignant syndrome, 793-798
 - sympathomimetic poisoning syndrome, 798-802
 - syndromes of, 789-804
 - general principles of, 785-789
 - malignant, drug-induced, 789-793
 - thermal homeostasis in, 785-786
 - treatment, 788-789
 - Hypertonic saline, for poisoning by sodium channel blocking agents, 845
 - Hypertonic sodium bicarbonate, sodium channel blocking agents and, 839-841
 - Hyperventilation, and ischemia, following traumatic brain injury, 175-177
 - for intracranial hypertension, 71-72
 - for traumatic brain injury, as acute temperature-normalizing measure, 179-180
 - cerebral ischemia due to, 163-184
 - chronic prophylactic, 177-179
 - institution of, 180
 - intermittent, for transient rises in ICP, 179
 - recommendations, 179-181
 - weaning, 180-181
 - prophylactic, chronic, following traumatic brain injury, 177-179
 - Hypotension, sodium channel blocking agent-related, treatment, 842-843
- ICP. *See Intracranial pressure.*
- ICUs. *See Intensive care units (ICUs).*
- Imipenem, seizures due to, 751-752
- Immobilization, in crotalid snake envenomation treatment, 902
- Immune system enhancers, following septic shock in children, 563
- Immunoglobulin(s), for Guillain-Barré syndrome, 12
- Immunonutrition, 677-678
- India, critical care in, 317-329
 - contributions by U.S. organizations to, 328
 - current status of, 318-320
 - ethical issues related to, 324-325
 - future of, 325-326
 - history of, 318-320
 - neonatal and pediatric, cost of, 343
 - current status of, 336-342
 - ethical issues in, 344
 - evaluation of, 333
 - evolution of, 331-346
 - existing facilities, 332-333
 - IAP program in, 342-343

- neonatal perinatal database in, 343-344
- PALS program in, 342-343
- successful collaboration in, factors contributing to, 344
- opportunities for global collaboration in, 326-328
- research in, 323-324
- spectrum of disease in, 320-323
- technology in, 323
- infant mortality rate in, 331
- National Neonatology Forum of, role in catalyzing neonatal intensive care, 333-334
- Neonatal Resuscitation Program of, 336
- population of, 331
- Indirect calorimetry, in nutritional status assessment, 670-671
- Indo-U.S. Faculty Exchange Program, 334-336
- Infants, acute renal failure in, causes, 577-578
- Infection. See also specific types.
- control of, in ICUs in Japan, 276-277
- nosocomial, in ICUs in Western Europe, 250
- Informed consent, ethical issues related to, 413
- Inhalational agents, and neuroprotection, 189-190
- Inhalational anesthesia, for status asthmaticus, 471-472
- Integrative group process (IGP), in critical care medicine, 434-435
- Intensive care. See also *Critical care*;
- Intensive care units (ICUs)*.
- defined, 236
- evolution of, 235-236
- future of, 242
- interaction with other specialties, 239
- international role of, 241-242
- value of, 237-239
- Intensive care medicine, societies of, in Europe, 251, 252
- Intensive care physicians. See *Intensivists*.
- Intensive care units (ICUs). See also *Critical care*.
- advocacy in, 698-699
- conflict between physicians and nurses in, 694-696
- consent and collaboration in, 692-694
- disaster medicine and, 241
- emergency department and, 240
- ethics in, 691-701
- Guillain-Barré syndrome in, management, 4, 5, 11
- in children, in Australia, 305
- in New Zealand, 305
- in East Asia, 290-295
- in Eastern Europe, 250-251
- in Europe, 245-254
- in Korea, 277-285. See also *Korea, ICUs in*.
- in Western Europe, 246-250. See also *Europe, Western, critical care in*.
- moral distress and burnout in, 697-699
- neurologic, transcranial Doppler ultrasonography in, 79-104. See also *Ultrasonography, transcranial Doppler, in neuro-critical care unit*.
- nurses in, 241
- training in, certification of units for, in Japan, 269
- undergraduate medicine and, 241
- Intensive care wards, in Japan, 269-277.
- See also *Japan, intensive care wards in*.
- current status of, 277
- Intensivists, board certification of, in Japan, 268-269
- ethical issues related to, 240
- rescue and, 240
- role of, 238
- transport and, 240
- triage and, 240
- value of, 237-239
- International federations, communications and, 444-445
- International organizations, communications and, 441-452. See also *Communications, international organizations and*.
- Internet connections, 445-451
- Intracerebral hemorrhage, acute blood pressure control in, 147-148
- described, 131
- edema with, 143-145
- hypertension in, 131-161
- α -adrenergic blockers for, 151
- β -adrenergic blockers for, 151
- ACE inhibitors for, 152-153
- antihypertensive agents for, 148-153
- calcium channel blockers for, 151-152
- diazoxide for, 150
- ganglionic blockers for, 150-151
- hydralazine for, 150
- nicardipine for, 152
- nimodipine for, 152
- nitroglycerin for, 150
- prevalence, 131-132
- sodium nitroprusside for, 149-150
- trimethaphan for, 150-151
- vasodilators for, 149-150
- ischemia in, 139-142
- PET in, 141
- SPECT in, 140-141
- systemic complications, 145
- thrombolytic therapy for, 215-217
- transcranial Doppler ultrasonography in, uses, 100
- Intracerebral hemorrhage enlargement, 142-143

- Intracranial hypertension, treatment, 71-73
- Intracranial pressure (ICP), and volume dynamics, 137-138
- elevation of, mannitol and, 120-121
- increased, hemodynamic response to, 138-139
- management, mannitol in, 113-118
- CSF dynamics and, 117-118
- diuretic theory of, 117
- general considerations, 113-114
- hemodynamic theory of, 115-117
- osmotic theory of, 114-115
- Intraoperative intracisternal irrigation, for subarachnoid hemorrhage, 213-214
- Intravenous gamma globulin (IVIg), for Guillain-Barré syndrome, 12
- Intraventricular conduction defects, sodium channel blocking agents and, 834
- Intraventricular hemorrhage, thrombolytic therapy for, 217-219
- Invasive positive pressure ventilation (IPPV), for ARDS, 510-511
- Inverse ratio ventilation, for ARDS, 512-513
- IPPV. See *Invasive positive pressure ventilation (IPPV)*.
- Ischemia, defined, 167-169
- following traumatic brain injury, evidence for, 174
- in intracerebral hemorrhage, 139-142
- Isoflurane, for status epilepticus, 29-30
- Isoniazid, seizures due to, 754-757
- IVOX, for ARDS, 515
- Japan, emergency medical services in, 273
- ICUs in, described, 277-279
- intensive care wards in, 267-277
- beds in, number of, 270-271
- board certification of intensive care physicians in, 268-269
- certification of units for intensive care training in, 269
- current status of, 270-277
- facilities in, 275-276
- Health and Welfare Ministry approval of, 269
- history of, 267-268
- infection control in, 276-277
- medical equipment and devices in, 274-275
- number of, 270
- nursing staff in, 273-274
- organization of, 272-273
- paramedical personnel in, 274
- physician specialties in, 272
- staffing of, 271-272
- Japanese Society of Intensive Care Medicine (JSICM), described, 268
- Jugular bulb catheter. See also *Jugular venous oxygen saturation (Sjvo₂)*, for cerebral hemodynamic monitoring.
- for cerebral hemodynamic monitoring, 51-77
- insertion of, 64-65
- maintenance of, 65
- Jugular venous blood, extracranial contamination of, 62-63
- mixing of, 62
- Jugular venous desaturation, diagnosis and management, 71
- Jugular venous oxygen saturation (Sjvo₂), changes in, with cerebral ischemia, 55-57
- with decreased arterial oxygen content, 52-55
- with increases in cerebral metabolic rate, 57-60
- during cardiovascular surgery, optimal values for, 69
- following head injury, optimal values for, 69-70
- for cerebral hemodynamic monitoring, 51-77
- complications, 67-68
- contraindications, 67
- indications, 65-67
- limitations, 73
- technical aspects of, 61-65
- ischemic thresholds for, 68-69
- normal values, 68
- Ketamine, and neuroprotection, 194-195
- Ketorolac, for pain in Guillain-Barré syndrome, 10
- Korea, critical care in, 277-285. See also *Korea, ICUs in.*
- ICUs in, academic activity and education for, 281-282
- application for revision of fees for medical treatment in, 284-285
- improvement ideas for, 284
- medical equipment and monitoring systems in, 282-283
- organization of, 279
- staffing of, 279-281
- intensive care wards in, 267-277
- Leptospirosis, in South American ICUs, 383
- Lidocaine, for status epilepticus, 31
- Lipid(s), in nutritional status assessment, 673
- Liquid ventilation, for ARDS, 516-517
- Liver abnormalities, in anticonvulsant hypersensitivity syndrome, 728-729

- Liver dysfunction, nutrition and, 680
 Lorazepam, for status epilepticus, 26
 Lymphadenopathy, in anticonvulsant hypersensitivity syndrome, 728
- Magnesium sulfate, for status asthmaticus, 467
 Malaria, in South American ICUs, 381-382
 Malignant hyperthermia, drug-induced, 789-793
 Mannitol, and midline shift, 123-124
 ICP elevation due to, 120-121
 in ICP management, 113-118
 in neurocritical care, uses, 113-119
 nonosmotic actions of, 111-112
 Mannitol drip, 119
 Massive transfusion syndrome, 603
 Mechanical ventilation, for ARF in AIDS patients, 536-537
 for status asthmaticus, 468-471
 complications, 471
 indications, 468
 modes of, 470
 muscle relaxants, 471
 permissive hypercapnia, 470-471
 tracheal intubation, 468-470
 in Guillain-Barré syndrome, criteria for, 6
 noninvasive, for status asthmaticus, 468
 Metabolic autoregulation, 164
 Metabolism, following septic shock in children, 562
 Methylprednisolone, for status asthmaticus, 465
 Methylxanthines, for status asthmaticus, 465-466
 Metronidazole, seizures due to, 757
 Mexilitine, for pain in Guillain-Barré syndrome, 11
 Midazolam, for status epilepticus, 27
 Minerals, in critically ill neurologic patients, 45
 MOPS, 312-313
 Moral distress, in ICU, 697-698
 Morphine, for pain in Guillain-Barré syndrome, 10
 Motor vehicle-related accidents, head injuries due to, 611
 Mucolytic therapy, for status asthmaticus, 468
 Muscle relaxants, to facilitate mechanical ventilation for unstable asthmatic patients, 471
 Musculoskeletal system, nerve agents effects on, 931
 Myalgia(s), in anticonvulsant hypersensitivity syndrome, 729
- Narcotics, for pain in Guillain-Barré syndrome, 10
 National Neonatology Forum of India, 333-334
 Near drowning, defined, 477
 Negative inotropic effect, sodium channel blocking agents and, 835
 Neonatal Resuscitation Program, in India, 336
 Neonates, critical care for, in India, 331-346. *See also India, critical care in, neonatal and pediatric.*
 Nerve agents, chemical properties of, 925
 mechanism of action of, 925-928
 poisoning by, 923-942
 assessment, 935-936
 cardiovascular effects of, 930-931
 clinical presentation, 928-932
 CNS effects of, 930
 dermal effects of, 932
 gastrointestinal effects of, 932
 genitourinary effects of, 932
 history of, 923-925
 laboratory studies, 932-933
 musculoskeletal effects of, 931
 ocular effects of, 931
 respiratory effects of, 929-930
 treatment, 933-938
 antidotal, 936-938
 atropine in, 936-937
 decontamination in, 934-935
 disposition in, 938
 pralidoxime chloride in, 937-398
 Neurointensive care, thrombolytic therapy in, 201-227
 transcranial Doppler ultrasonography in, 79-104
 Neuroleptic malignant syndrome, drug-induced, 793-798
 versus serotonin syndrome, 776, 777
 Neuroprotection, intravenous agents and, 185-199. *See also Brain protection.*
 Neurotoxicity, 897
 crotalid snake envenomation and, 901
 New Zealand, critical care in, 299-316
 consultants for, 303-304
 international links in, 313-314
 manpower for, 307-309
 nurses in, 304-305
 organization of, 302-305
 pediatric, 305
 quality assurance in, 310-312
 staffing of, 302-305
 training for, 306-307
 FICANZCA program, 307
 RACP program, 306-307
 health system organization in, 300-301
 population of, 300
 Newborns, acute renal failure in, causes, 577-578

- Nicardipine, for hypertension in intracerebral hemorrhage, 152
- Nicotine, poisoning by, 870-875
structure of, 873
- NIH health technology assessment, 420-421
- Nimodipine, for hypertension in intracerebral hemorrhage, 152
- Nitric oxide, for ARDS, 515-516
- Nitrogen, in critically ill neurologic patients, 41
- Nitroglycerin, for hypertension in intracerebral hemorrhage, 150
- Nominal group technique, in critical care medicine, 433
- Nonpacemaker cells, 831-833
- Nortriptyline, for pain in Guillain-Barré syndrome, 11
- Nosocomial infection, in ICUs in Western Europe, 250
- Nurse(s), in ICUs, in Australia, 304-305
in Japan, 273-274
role of, 241
training for, in Africa, 256-257
- Nutritional management, in Guillain-Barré syndrome, 9-10
of critically ill neurologic patients, 39-49
calorie requirements, 40-41
early feeding, 45-47
fat versus carbohydrate calories, 44-45
high-protein enteral feedings, 41-45
minerals, 45
nitrogen requirements, 41
parenteral versus enteral nutrition, 47-48
vitamins, 45
- Nutritional status, 669-690
assessment, 669-672
anthropometry in, 670
arginine in, 677
biochemical markers in, 670-671
glutamine in, 677
indirect calorimetry in, 670-671
multiparameter tools in, 671
omega-3 fatty acids in, 678
RNA in, 677
substrates in, 672-676
burns and, 680
caloric requirements for, 673-674
carbohydrates in, 673-674
cardiovascular disease and, 677-680
following septic shock in children, 562
immunonutrition, 677-678
lipids in, 675
liver dysfunction and, 680
organ system issues in, 678-682
proteins in, 675-676
renal failure and, 681-682
respiratory failure and, 678-679
route-related complications in, 676-678
sepsis and, 680
wound healing and, 682
- Oleandrin, structure of, 860
- Omega-3 fatty acids, in nutritional status assessment, 678
- Osmotherapy, 105-129. See also *Osmotic agents*.
adverse acute hemodynamic effects of, 119-126
and brain pathology, 110-111
chemical debulking in, 118
dehydration due to, 121-122
electrolyte disturbances due to, 121-122
hemorrhheologic effects of, 119
historical background of, 106-107
limitations, 119-126
pharmacokinetics, 112-113
pitfalls of, 119-126
rebound phenomenon of, 125-126
renal clearance in, 112-113
- Osmotic agents, actions of, 107-112
and tonicity, 108-109
delivery of, 105-129. See also *Osmotherapy*.
effects of, 107-108
hemorrhheologic effects, 119
- Oximetry, in vivo, 60-61
- Oxygen, for status asthmaticus, 463-464
- Oxygen metabolism, and cerebral blood flow, relationship between, 165-167
- Pacemaker cells, 833
- Pain, chest. See *Chest pain*.
in Guillain-Barré syndrome, control of, 10-11
- Paraldehyde, for status epilepticus, 30-31
- Paramedical personnel, in ICUs in Japan, 274
- Parenteral nutrition, versus enteral nutrition, in critically ill neurologic patients, 47-48
- PEEP. See *Positive end-expiratory pressure (PEEP)*.
- Penicillin(s), seizures due to, 745-749
- Pentameth isethionate, for ARF in AIDS patients, 532
- Pentobarbital, for status epilepticus, 29
- Peripheral anticholinergic syndrome, 877
- Permissive hypercapnia, for ARDS, 512
for status asthmaticus, 470-471
- PET. See *Positron emission tomography (PET)*.
- Pharmacologic agents, for ARDS, 517-518
- Phenobarbital, for status epilepticus, 28
hypersensitivity associated with, 730

- structure of, 735
- Phenobarbital hypersensitivity, 730
- Phenytoin, for status epilepticus, 27-28
 - rashes associated with, 729-730
 - structure of, 735
- Phytolaccagenin from poke, structure of, 881
- Plant poisoning, life-threatening, 849-888
 - aconitine in, 867-870
 - anticholinergics in, 875-879
 - cardiac glycosides in, 859-862
 - cicutoxin in, 854-858
 - grayanotoxins in, 862-864
 - management, 849-850
 - nicotine in, 870-875
 - saponin glycosides in, 879-883
 - toxalbumins in, 850-854
 - Veratrum* alkaloids in, 864-867
- Plasma exchange, for Guillain-Barré syndrome, 11-12
- Pneumocystis carinii* pneumonia, ARF
 - secondary to, 527
- Pneumonia, *Pneumocystis carinii*, ARF
 - secondary to, 527
- Pneumonitis, in anticonvulsant hypersensitivity syndrome, 729
- Pneumothorax, spontaneous, as complication of respiratory failure in AIDS patients, 537-538
- Poison(s), in South American ICUs, 382
- Poisoning, 647-667
 - advanced supportive techniques for, 659-662
 - antidotes for, 655-658
 - basic supportive care for, 649-653
 - by sodium channel blocking agents, 829-848. See also *Sodium channel blocking agents, poisoning by*.
 - gastrointestinal decontamination following, 709-725. See also *Gastrointestinal decontamination, following poisoning*.
 - nerve agent, 923-942. See also *Nerve agents, poisoning by*.
 - plant, life-threatening, 849-888. See also *Plant poisoning, life-threatening*.
 - treatment, novel approaches to, 658-659
- Positive end-expiratory pressure (PEEP), for ARDS, 511-513
- Positron emission tomography (PET), in intracerebral hemorrhage, 141
- Pralidoxime chloride, in nerve agent poisoning treatment, 937-398
- Pressure autoregulation, 165
- Pressure immobilization, in crotalid snake envenomation treatment, 903
- Primaquine, for ARF in AIDS patients, 534
- Primary fibrin(ogen)olysis, 598-600
- Propofol, and neuroprotection, 192-194
 - for status epilepticus, 30
- Protein(s), in nutritional status assessment, 675-676
- Protoverine, structure of, 866
- Purpura fulminans, following septic shock in children, 561-562
- QRS prolongation, sodium channel blocking agent-related, treatment, 842
- Quality assurance, in ICUs in Australia and New Zealand, 310-312
- RACP program, in Australia, 306-307
- RAND appropriateness rating method, in critical care medicine, 435-436
- Rash(es), in anticonvulsant hypersensitivity syndrome, 728
 - phenytoin and, 729-730
- Renal clearance, in osmotherapy, 112-113
- Renal dysfunction, in anticonvulsant hypersensitivity syndrome, 729
- Renal failure, nutrition and, 680-681
 - septic shock in children effects on, 560-561
- Renal hypoperfusion, acute renal failure due to, 576-579
- Reperfusion, 186
- Rescue, intensivists role in, 240
- Respiratory failure, acute. See *Acute respiratory failure (ARF)*.
 - in Guillain-Barré syndrome, 4-8
 - nutrition and, 678-679
 - septic shock in children effects on, 560
- Respiratory system, nerve agents effects on, 929-930
- Resuscitation, following head injury, 620-622
- Rhabdomyolysis, in anticonvulsant hypersensitivity syndrome, 729
- Ricin, poisoning by, 850-854
- Ricinus communis*, poisoning by, 850-854
- Ritipenem (FCE22101), seizures due to, 751-752
- RNA, in nutritional status assessment, 677
- rt-PA, for stroke, 205
- Saponin glycosides, poisoning by, 879-883
- Schistosomiasis, in South American ICUs, 380-381
- Scopolamine, structure of, 876
- Secondary drowning, defined, 477-478
- Seizure(s), antibiotic-induced, 741-762. See also *Convulsion(s), antibiotic-induced*.
 - following head injury, 619-620
- Seizure disorders, submersion accidents in patients with, 479

- Sepsis, and ARDS, 507-508
 following trauma, in South American ICUs, 383
 nutrition and, 680
- Septic shock, 553-574
 in adults, 563-568
 adrenal insufficiency following, 567
 airway and breathing following, 565
 antibiotics following, 567-568
 cardiovascular therapy following, 566-567
 pathogenesis, 564
 predisposing factors, 564-565
 prevention, 565
 recognition of, 565
 resuscitation following, 565-568
 stabilization following, 568
 volume resuscitation following, 565-566
 in children, 553-563
 adrenal insufficiency following, 558
 airway and breathing following, 557
 antibiotic therapy following, 558
 cardiovascular failure following, 558-560
 cardiovascular therapy following, 557-558
 DIC following, 561-562
 drug metabolism following, 562
 early recognition of, 556-557
 electrolyte balance following, 562
 extracorporeal therapies following, 562
 factors predisposing to, 555-556
 immune system enhancers following, 563
 metabolism following, 562
 nutritional needs following, 562
 pathogenesis, 553-555
 prevention, 556
 purpura fulminans following, 561-562
 renal failure following, 560-561
 respiratory failure following, 560
 resuscitation following, 557-558
 stabilization following, 558-563
 volume resuscitation following, 557
- Serotonergic potential of drugs, 771
- Serotonin, anatomy related to, 767
 function of, 765-766
 metabolism of, 767-768
 physiology of, 765-769
 psychopharmacology of, 770-773
 synthesis of, 767-768
- Serotonin receptors, 768-769
- Serotonin syndrome, 763-783
 ancillary tests, 775-776
 clinical presentation, 773-775
 described, 763
 diagnosis, 764-765
 differential diagnosis, 776
 history of, 764
 laboratory tests, 775-776
 pathophysiology, 769-770
 treatment, 776, 778-779
 versus neuroleptic malignant syndrome, 776, 777
- Shock, septic. *See Septic shock.*
- Single photon emission computed tomography (SPECT), in intracerebral hemorrhage, 140-141
- Sinus venous thrombosis, dural, 219-221
- Skin, nerve agents effects on, 932
- Snake bites, in South American ICUs, 382
 prevalence, 889
- Snake venom extractors, in crotalid snake envenomation treatment, 904
- Society of Critical Care Medicine (SCCM), establishment of, 367, 369-370
 role of, 370-371
- Sodium channel(s), voltage-gated, and cardiac action potentials, 830-833
- Sodium channel blocking agents, bradyarrhythmia due to, 835-836
 hypertonic sodium bicarbonate and, 839-841
- intraventricular conduction defects due to, 834
 myocardial toxicity due to, 833-838
 negative inotropic effect due to, 835
 poisoning by, 829-848
 bradyarrhythmias due to, treatment, 844-845
 features, 838
 hypertonic saline for, 845
 hypotension due to, treatment, 842-843
 QRS prolongation due to, treatment, 842
 supraventricular tachyarrhythmias due to, treatment, 845
 treatment, 841-845
 ventricular arrhythmias due to, treatment, 843-844
 tachyarrhythmia effects on, 836-838
 ventricular arrhythmias due to, 834
- Sodium nitroprusside, for hypertension in intracerebral hemorrhage, 149-150
- Solmedrol, for pain in Guillain-Barré syndrome, 10
- South America, critical care in, 377-387
 amebiasis in, 380
 ascariasis in, 380
 Chagas' disease in, 383
 dengue hemorrhagic fever in, 382
 enteritis in, 381
 Federacion Panamericana y Iberica de Medicina Critica y Terapia Intensiva in, 377-379
 future of, 386-387
 government's role in, 385

- hookworm disease in, 380
- leptospirosis in, 383
- malaria in, 381-382
- organization and funding of health care in, 383-384
- poisons in, 382
- population in, 380-383
- proposed solutions in, 386
- schistosomiasis in, 380-381
- sepsis following trauma in, 383
- snake bites in, 382
- survey on, 379
- technology in, 384-385
- tetanus in, 382
- tuberculosis in, 381
- within health care, 385-386
- Specialty, characteristics of, 236-237
- SPECT. *See* Single photon emission computed tomography (SPECT).
- Starling forces, blood-brain barrier and, 109
- State-of-the-Art method, in critical care medicine, 436
- Status asthmaticus, 459-476. *See also* Asthma.
 - management, 463-472
 - β_2 -agonists, 464-465
 - anticholinergic agents, 466
 - bronchoscopy, 468
 - corticosteroids, 465
 - cromones, 467
 - ECMO, 468
 - furosemide, 467
 - future approaches to, 472
 - heliox, 467
 - inhalational anesthesia, 471-472
 - magnesium sulfate, 467
 - mechanical ventilatory support, 468-471
 - methylxanthines, 465-466
 - oxygen, 463-464
- Status epilepticus, 17-38, 629-646
 - classification of, 18, 19, 631-633
 - clinical manifestations, 636-638
 - defined, 17
 - diagnostic approach to, 638-639
 - EEG changes in, 22-24
 - epidemiology, 18-19, 629-631
 - historical background of, 17-18
 - management, 639-644
 - pathogenesis, 633-636
 - pathophysiology, 19-22, 633-636
 - prognosis, 33-35
 - radiographic scan changes in, 24
 - treatment, clonazepam, 27
 - complications, 32-33
 - diazepam, 26
 - etomidate, 30
 - fosphenytoin, 27-28
 - future of, 35
 - general considerations, 24-25
 - isoflurane, 29-30
 - lidocaine, 31
 - lorazepam, 26
 - midazolam, 27
 - paraldehyde, 30-31
 - pentobarbital, 29
 - pharmacotherapy, 25-31
 - phenobarbital, 28
 - phenytoin, 27-28
 - propofol, 30
 - protocol for, 31-32
 - thiopental, 28-29
- Streptokinase, for stroke, 206
- Stroke, described, 201-202
 - incidence, 201
 - mortality rates, 201
 - rt-Pa for, 205
 - streptokinase for, 206
 - thrombolytic therapy for, 202-211
- Subarachnoid hemorrhage, cerebral
 - vasospasm following, development of, 87-88
 - inoperable, high-grade, 215
 - management, transcranial Doppler ultrasonography in, 92-93
 - thrombolytic therapy for, 211-215
- Submersion injuries, 477-502
 - epidemiology, 478-481
 - future directions related to, 497-498
 - in bathtubs, 481
 - in buckets, 481
 - in children, prevalence, 478-479
 - prevention, 481-485
 - drowning safety enactment in, 484-485
 - education in, 481-482
 - personal safety enforcement in, 485
 - public health engineering in, 483
 - in hot tubs, 481
 - in natural bodies of water, 480-481
 - in spas, 481
 - in swimming pools, 479
 - management, 491-497
 - at scene, 491-493
 - cardiovascular, 495-496
 - emergency department care, 493-494
 - ICU, 494
 - neurologic resuscitation, 496-497
 - respiratory, 494-495
 - neurologically based problems in, 486-487
 - pathophysiology, 485-489
 - prognostic predictors following, 489-491
 - seizure disorders and, 479
- Substrate(s), 672-676
 - metabolism of, in nutritional status assessment, 672-673
- Supraventricular tachyarrhythmias, sodium channel blocking
 - agent-related, treatment, 845

- Surfactant(s), for ARDS, 515
- Suxamethonium, in Guillain-Barré syndrome, 9
- Sympathomimetic poisoning syndrome, drug-induced, 798-802
- Tachyarrhythmia(s), effects on sodium channel blocking agents, 836-838
- supraventricular, sodium channel blocking agent-related, treatment, 845
- Technologists, training for, in Africa, 257
- Tetanus, in South American ICUs, 382
- Theophylline, for status asthmaticus, 465-466
- Thermal homeostasis, hyperthermia and, 785-786
- Thiopental, for status epilepticus, 28-29
- Thrombocytopenia, crotalid snake envenomation and, 896-897
- Thrombolysis, intraarterial, for stroke, 209-211
- intravenous, for stroke, 202-209
- Thrombolytic therapy, for intracerebral hemorrhage, 215-217
- for intraventricular hemorrhage, 217-219
- for subarachnoid hemorrhage, 211-215
- in neurointensive care, 201-227
- recommendations, 221
- stroke-related applications of, 221
- Thrombosis, dural sinus venous, 219-221
- Thrombotic thrombocytopenic purpura (TTP), 597-598
- Thyroiditis, in anticonvulsant hypersensitivity syndrome, 729
- TMP-SMZ. See *Trimethoprim-sulfamethoxazole (TMP-SMZ)*.
- Toddlers, submersion injuries in, 478-479
- Tonicity, and osmotic reflection, 108-109
- Tourniquets, in crotalid snake envenomation treatment, 903-904
- Toxalbumin(s), poisoning by, 850-854
- Toxin removal, acceleration of, 653-655
- Tracheal intubation, for status asthmaticus, 468-470
- Transport, intensivists role in, 240
- Trauma, head. See *Head trauma*.
- sepsis following, in South American ICUs, 383
- Traumatic brain injury, cerebral blood flow following, 171-172
- cerebral metabolism following, 172
- costs of care following, 163
- head injury and, 613-614
- incidence, 163
- ischemia following, evidence for, 174
- hyperventilation and, 175-177
- monitoring A-VDO₂ in, 172-174
- prevalence, 163
- problems related to, 163
- studies in, 171-174
- treatment, cerebral ischemia due to, 163-184
- Triage, ethical issues related to, 410-411
- intensivists role in, 240
- Trimethaphan, for hypertension in intracerebral hemorrhage, 150-151
- Trimethoprim-sulfamethoxazole (TMP-SMZ), for ARF in AIDS patients, 531-532
- Trimetrexate, for ARF in AIDS patients, 533-534
- Tuberculosis, in South American ICUs, 381
- Ultrasonography, transcranial Doppler, cerebral vasospasm detection by, 88-91
- in acute cerebral ischemia, uses and considerations, 99-100
- in brain death determination, 98-99
- in examination of cerebral vessels, 82-87
- in head trauma, 93-94
- uses, 97-98
- in intracerebral hemorrhage, uses, 100
- in neuro-critical care unit, 79-104
- future directions in, 93
- limitations, 87
- in subarachnoid hemorrhage management, 92-93
- limitations, in vasospasm monitoring, 91-92
- principles of, 80-82
- waveforms, in head trauma, 94-97
- Undergraduate medicine, intensive care unit and, 241
- United States, critical care in, 363-376
- accomplishments of, 371-372
- Canadian critical care and, comparison between, 350-359
- current status of, 365-367
- future research for, 372
- historical background of, 363-365
- impact of changing health care system on, 372-374
- Society of Critical Care Medicine in, 367, 369-371
- Valproate, for anticonvulsant hypersensitivity syndrome, 737
- Valproic acid, for pain in Guillain-Barré syndrome, 11
- Vasodilating agents, for hypertension in intracerebral hemorrhage, 149-150

- Vasospasm, cerebral. See *Cerebral vasospasm*.
- Ventilation, airway pressure release, 515
 high-frequency, for ARDS, 513-514
 inverse ratio, for ARDS, 512-513
 liquid, for ARDS, 516-517
 mechanical. See *Mechanical ventilation*.
- Ventricular arrhythmias, sodium channel blocking agent-related, 834
 treatment, 843-844
- Veratrum* alkaloids, poisoning by, 864-867
- Vigabatrin, for anticonvulsant hypersensitivity syndrome, 737
- Vitamin(s), in critically ill neurologic patients, 45
- Vitamin K-related disorders, 600-602
 causes, 600-601
 clinical presentation, 601-602
 management, 602
 pathophysiology, 600-601
- Volume resuscitation, following septic shock in adults, 565-566
- Warfarin, anticoagulant effects of, 603-605
 Western Europe, critical care in, 246-250.
 See also *Europe, Western, critical care in*.
- Whole bowel irrigation, in gastrointestinal decontamination following poisoning, 722
- Withdrawal of treatment, ethical issues related to, 412-413
- Withholding of treatment, ethical issues related to, 412-413
- Wound healing, nutrition and, 682